Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction

OBJECTIVES: To investigate the acute effect of phosphodiesterase type 5 (PDE5) inhibitor on erectile dysfunction by evaluating serum oxidative status and prolidase activity. METHODS: Serum samples of 36 patients with erectile dysfunction and 30 control cases were analyzed for total antioxidant status, total oxidant status, and prolidase activity, before and after the administration of tadalafil citrate. RESULTS: Before and after tadalafil citrate administration, serum total antioxidant status, total oxidant status, and prolidase were 1.1±0.0 vs. 1.6±0.0 µmol H2O2 Eq/L, 10.3±1.1 vs. 6.9±1.2 µmol H2O2 Eq/L, and 236.4±19.5 vs. 228.2±19.2 U/L, respectively (p<0.0001 for all). CONCLUSIONS: Evaluation of serum oxidative status and prolidase activity confirmed the beneficial acute effects of PDE5 inhibitor in patients with erectile dysfunction.

[1]  H. Çelik,et al.  The association of serum prolidase activity and erectile dysfunction. , 2010, Journal of andrology.

[2]  A. Shindel.  Serum Biomarker Measurements of Endothelial Function and Oxidative Stress After Daily Dosing of Sildenafil in Type 2 Diabetic Men With Erectile Dysfunction , 2010 .

[3]  M. Ferrini,et al.  Early onset of fibrosis within the arterial media in a rat model of type 2 diabetes mellitus with erectile dysfunction , 2009, BJU international.

[4]  N. Gonzalez-Cadavid.  Mechanisms of penile fibrosis. , 2009, The journal of sexual medicine.

[5]  S. Biswal,et al.  Sildenafil inhibits superoxide formation and prevents endothelial dysfunction in a mouse model of secondhand smoke induced erectile dysfunction. , 2009, The Journal of urology.

[6]  G. Zummo,et al.  Role of oxidative and nitrosative stress biomarkers in chronic heart failure. , 2009, Frontiers in bioscience.

[7]  M. Nazıroğlu,et al.  Sildenafil citrate as a phosphodiesterase inhibitor has an antioxidant effect in the blood of men , 2008, Journal of clinical pharmacy and therapeutics.

[8]  A. Patruno,et al.  Phosphodiesterase Type-5 Inhibitor and Oxidative Stress , 2008, International journal of immunopathology and pharmacology.

[9]  O. Erel,et al.  The association of serum prolidase activity with the presence and severity of coronary artery disease , 2008, Coronary artery disease.

[10]  B. Turgut,et al.  The effect of sildenafil on the altered thoracic aorta smooth muscle responses in rat pre-eclampsia model. , 2008, European journal of pharmacology.

[11]  K. Salnikow,et al.  Extracellular matrix and HIF‐1 signaling: The role of prolidase , 2008, International journal of cancer.

[12]  D. Webb,et al.  Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients , 2008, Journal of hypertension.

[13]  N. Aksoy,et al.  Serum prolidase activity in patients with hypertension and its relation with left ventricular hypertrophy. , 2007, Clinical biochemistry.

[14]  G. Watts,et al.  Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus , 2007, Diabetes & vascular disease research.

[15]  D. Udelson,et al.  A three-dimensional theoretical model of the relationship between cavernosal expandability and percent cavernosal smooth muscle. , 2007, The journal of sexual medicine.

[16]  B. Zhu,et al.  The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary/cardiovascular vessels. , 2007, Current topics in medicinal chemistry.

[17]  H. Çelik,et al.  Increased oxidative stress and its relation with collagen metabolism in knee osteoarthritis , 2007, Rheumatology International.

[18]  P. Yazgan,et al.  Correlations of serum prolidase activity between bone turnover markers and mineral density in postmenopausal osteoporosis , 2006, Archives of Gynecology and Obstetrics.

[19]  O. Erel,et al.  A new automated colorimetric method for measuring total oxidant status. , 2005, Clinical biochemistry.

[20]  G. Frajese,et al.  New achievement and novel therapeutic applications of PDE5 inhibithors in older males. , 2005, Journal of endocrinological investigation.

[21]  O. Erel,et al.  A novel automated method to measure total antioxidant response against potent free radical reactions. , 2004, Clinical biochemistry.

[22]  P. Sienkiewicz,et al.  Oxidative stress induces IGF-I receptor signaling disturbances in cultured human dermal fibroblasts. A possible mechanism for collagen biosynthesis inhibition. , 2004, Cellular & molecular biology letters.

[23]  R. Kloner,et al.  Sildenafil in patients with cardiovascular disease. , 2003, The American journal of cardiology.

[24]  G. Broderick,et al.  Diabetes and vascular impotence: does insulin dependence increase the relative severity? , 1999, International Journal of Impotence Research.

[25]  T. Osawa,et al.  [Oxidative stress and atherosclerosis]. , 1997, Nihon rinsho. Japanese journal of clinical medicine.

[26]  T. Lue.  Veno-occlusive dysfunction of corpora cavernosa: comparison of diagnostic methods. , 1996, The Journal of urology.

[27]  N. Moatti,et al.  Human kidney prolidase--purification, preincubation properties and immunological reactivity. , 1994, The International journal of biochemistry.

[28]  J. Rajfer,et al.  Prevalence of corporeal venous leakage in impotent men. , 1988, The Journal of urology.

[29]  F. Chinard.  Photometric estimation of proline and ornithine. , 1952, The Journal of biological chemistry.

[30]  J. A. Robinson.  Clinics , 1883, The Dental register.